Metropolis Healthcare announced a 23% year-on-year increase in Group revenue for Q2 FY26. The company’s organic revenue grew by 12%, with EBITDA margin improving to 26.8%. The B2C segment contributed 59% of total revenues. The company is focused on margin expansion, operational efficiency, and strengthening its specialty testing capabilities. Metropolis aims to maintain its top-line growth and leadership position.
Financial Performance Highlights
Metropolis Healthcare reported strong financial results for Q2 FY26, showcasing robust growth and improved profitability:
- Group Revenue: Grew by 23% year-on-year.
- Organic Revenue Growth: 12%.
- EBITDA Margin: Stood at 26.8%, an improvement of 60 bps compared to Q2 FY25.
- B2C Contribution: 59% of total revenue, with 11% year-on-year growth.
- B2B Growth: 14% year-on-year for organic business.
Segment Performance
Key segments demonstrated strong performance:
- TruHealth: Revenue grew by 21% year-on-year for organic business.
- Specialty: Revenue increased by 15% year-on-year for organic business.
Strategic Focus and Expansion
Metropolis Healthcare is focused on several strategic initiatives to drive future growth:
- Margin Expansion: Through better cost controls, improved test mix, and automation.
- New Markets: Expanding presence in Tier 2 and Tier 3 cities, adding 300 new collection centers in H2 FY26.
- Specialized Testing: Strengthening high-end capabilities, including AI-based allergy testing and genomics.
- Operational Efficiency: Integrating digital and AI-driven tools to enhance service quality.
Outlook and Guidance
Metropolis Healthcare aims to maintain its top-line guidance and expects to meet stated estimates in H2 FY26. The company is confident in its ability to further build and reinforce its leadership position nationwide.
Source: BSE
